Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
205 participants
OBSERVATIONAL
2017-01-31
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Pupil Light Responses in Patients With Parkinson Disease
NCT04117555
Development of Digital Diagnostic Devices for Parkinson's Disease
NCT06663826
Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease
NCT02640339
Study for the Early Diagnosis of Parkinson's Disease
NCT02283073
Retinal Function in Parkinson's Disease
NCT01010074
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Parkinson's Disease
No interventions assigned to this group
Control
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy controls without neurological illness
Exclusion Criteria
* dementia
* have an exposure to neuroleptic medications other than Quetiapine or Clozapine in the 6 months prior to screening
* have an active eye infection or have had eye surgery within 3 months prior to screening
* control subjects will be excluded if they have a history of neurological disease
* PD subjects will be excluded if they have an atypical Parkinsonian syndrome
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Southern California
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sarah Hamm-Alvarez
Professor and Vice Chair, Basic Research; Associate Dean, Basic and Translational Research; Director, Research development
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Southern California
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hamm-Alvarez SF, Janga SR, Edman MC, Feigenbaum D, Freire D, Mack WJ, Okamoto CT, Lew MF. Levels of oligomeric alpha-Synuclein in reflex tears distinguish Parkinson's disease patients from healthy controls. Biomark Med. 2019 Dec;13(17):1447-1457. doi: 10.2217/bmm-2019-0315. Epub 2019 Sep 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11594
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.